Distinguished in Sertoli-Leydig Cell Tumor

Dr. John P. Diaz

Gynecologic Oncology | Oncology
South Miami Gyn Oncology Physicians, LLC
6200 Sw 73rd St, South Miami Gyn Oncology, 
South Miami, FL 
Accepting New Patients
Offers Telehealth
Distinguished in Sertoli-Leydig Cell Tumor
South Miami Gyn Oncology Physicians, LLC
6200 Sw 73rd St, South Miami Gyn Oncology, 
South Miami, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

John Diaz is a Gynecologic Oncologist and an Oncologist in South Miami, Florida. Dr. Diaz is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, and Hysterectomy. Dr. Diaz is currently accepting new patients.

His clinical research consists of co-authoring 32 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Oncology
Licenses
Obstetrics & Gynecology in NY
Hospital Affiliations
South Miami Hospital
Baptist Hospital Of Miami
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

SOUTH MIAMI GYN ONCOLOGY PHYSICIANS, LLC
6200 Sw 73rd St, South Miami Gyn Oncology, South Miami, FL 33143
Other Locations
SOUTH MIAMI GYN ONCOLOGY PHYSICIANS, LLC
8900 N Kendall Dr, South Miami Gyn Oncology, Miami, FL 33176
SOUTH MIAMI GYN ONCOLOGY PHYSICIANS, LLC
1228 S Pine Island Rd, Suite 410, Plantation, FL 33324

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Dostarlimab, Carboplatin, Paclitaxel, Niraparib
Study Phase: Phase 3
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
Enrollment Status: Completed
Publish Date: August 20, 2025
Intervention Type: Drug
Study Drug: STRO-002
Study Phase: Phase 1
Immunotherapy in Combination With PARP Inhibition in Advanced Cervical Cancer Patients Functionally Competent or Deficient for the Fanconi Anemia Repair Pathway
Immunotherapy in Combination With PARP Inhibition in Advanced Cervical Cancer Patients Functionally Competent or Deficient for the Fanconi Anemia Repair Pathway
Enrollment Status: Terminated
Publish Date: April 29, 2025
Intervention Type: Drug
Study Drugs: Pembrolizumab, Olaparib
Study Phase: Phase 2
FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects With Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects With Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Enrollment Status: Terminated
Publish Date: March 24, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
A Phase 2 Study of Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2025
Intervention Type: Drug
Study Drugs: VS-6766, Defactinib
Study Phase: Phase 2
Standard Chemotherapy Versus Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
Standard Chemotherapy Versus Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 22, 2024
Intervention Type: Diagnostic test, Drug
Study Drug: Standard Chemotherapy
Study Phase: Phase 3
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Upifitamab rilsodotin
Study Phase: Phase 1/Phase 2
Evaluating Immune Checkpoint Inhibition In Solid Tumor Patients With Homologous Recombination Repair Deficiency
Evaluating Immune Checkpoint Inhibition In Solid Tumor Patients With Homologous Recombination Repair Deficiency
Enrollment Status: Completed
Publish Date: October 19, 2023
Intervention Type: Drug
Study Phase: Phase 2
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen
Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen
Enrollment Status: Completed
Publish Date: May 06, 2023
Intervention Type: Drug
Study Drug: Tisotumab vedotin
Study Phase: Phase 2
A Single Center, Prospective, Randomized, Controlled Study To Evaluate Physician Preference Related to the Use of the SURGIQUEST AIRSEAL® INSUFFLATION SYSTEM (AIS) at Low VS. Higher Pressure for the Management of Pneumoperitoneum.
A Single Center, Prospective, Randomized, Controlled Study To Evaluate Physician Preference Related to the Use of the SURGIQUEST AIRSEAL® INSUFFLATION SYSTEM (AIS) at Low VS. Higher Pressure for the Management of Pneumoperitoneum.
Enrollment Status: Completed
Publish Date: November 13, 2019
Intervention Type: Device
Study Phase: Not Applicable
View 9 Less Clinical Trials

32 Total Publications

Preoperative immunonutrition for patients who undergo primary cytoreductive surgery for ovarian cancer.
Preoperative immunonutrition for patients who undergo primary cytoreductive surgery for ovarian cancer.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: March 13, 2025
Similar Doctors
Distinguished in Sertoli-Leydig Cell Tumor
Dr. Matthew P. Schlumbrecht
Gynecologic Oncology | Obstetrics and Gynecology
Distinguished in Sertoli-Leydig Cell Tumor
Dr. Matthew P. Schlumbrecht
Gynecologic Oncology | Obstetrics and Gynecology

University Of Miami

1601 Nw 12th Ave, 
Miami, FL 
 (7.8 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Matthew Schlumbrecht is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Miami, Florida. Dr. Schlumbrecht is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Sertoli-Leydig Cell Tumor, and Hysterectomy. Dr. Schlumbrecht is currently accepting new patients.

Brian M. Slomovitz
Distinguished in Sertoli-Leydig Cell Tumor
Dr. Brian M. Slomovitz
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Sertoli-Leydig Cell Tumor
Dr. Brian M. Slomovitz
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Physician Practices Of Msmc LLC

4306 Alton Rd, Fl 3, 
Miami Beach, FL 
 (12.4 miles away)
305-535-3310
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Brian Slomovitz is a Gynecologic Oncologist and an Oncologist in Miami Beach, Florida. Dr. Slomovitz is rated as an Elite provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. His top areas of expertise are Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Hysterectomy, and Lymphadenectomy. Dr. Slomovitz is currently accepting new patients.

Distinguished in Sertoli-Leydig Cell Tumor
Dr. Joseph M. Pearson
Gynecologic Oncology | Surgical Oncology | Obstetrics and Gynecology
Distinguished in Sertoli-Leydig Cell Tumor
Dr. Joseph M. Pearson
Gynecologic Oncology | Surgical Oncology | Obstetrics and Gynecology

University Of Miami

1601 Nw 12th Ave, 
Miami, FL 
 (7.8 miles away)
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Joseph Pearson is a Gynecologic Oncologist and a Surgical Oncologist in Miami, Florida. Dr. Pearson is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. His top areas of expertise are Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Malignant Mixed Mullerian Tumor, Oophorectomy, and Hysterectomy. Dr. Pearson is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Diaz's expertise for a condition
ConditionClose
    View All 18 Advanced Conditions
    View All 26 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile